Major Depressive Disorder

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

Jain discussed Rejoyn, the FDA-approved digital therapeutic app that enhances major depressive disorder treatment with engaging brain training and mindfulness exercises.

Alto Neuroscience developed an EEG biomarker that predicts placebo response in MDD trials, potentially improving drug effect detection and reducing trial variability.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

A study links daily discrimination to greater depression and anxiety rates, with marginalized groups facing greater mental health risks across the US.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

A new study found antidepressant use drops by nearly 50% during pregnancy, but without increased psychotherapy, raising concerns about untreated depression risks.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.